Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study.
Deegan PB, Goker-Alpan O, Geberhiwot T, Hopkin RJ, Lukina E, Tylki-Szymanska A, Zaher A, Sensinger C, Gaemers SJM, Modur V, Thurberg BL, Sharma J, Najafian B, Mauer M, DasMahapatra P, Wilcox WR, Germain DP. Deegan PB, et al. Among authors: modur v. Mol Genet Metab. 2023 Feb;138(2):106963. doi: 10.1016/j.ymgme.2022.11.002. Epub 2022 Nov 9. Mol Genet Metab. 2023. PMID: 36481125 Free PMC article. Clinical Trial.
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
Gansevoort RT, Hariri A, Minini P, Ahn C, Chapman AB, Horie S, Knebelmann B, Mrug M, Ong ACM, Pei YPC, Torres VE, Modur V, Antonshchuk I, Perrone RD. Gansevoort RT, et al. Among authors: modur v. Am J Kidney Dis. 2023 May;81(5):517-527.e1. doi: 10.1053/j.ajkd.2022.10.016. Epub 2022 Dec 17. Am J Kidney Dis. 2023. PMID: 36535535 Free article. Clinical Trial.
Correction of cilia structure and function alleviates multi-organ pathology in Bardet-Biedl syndrome mice.
Husson H, Bukanov NO, Moreno S, Smith MM, Richards B, Zhu C, Picariello T, Park H, Wang B, Natoli TA, Smith LA, Zanotti S, Russo RJ, Madden SL, Klinger KW, Modur V, Ibraghimov-Beskrovnaya O. Husson H, et al. Among authors: modur v. Hum Mol Genet. 2020 Aug 29;29(15):2508-2522. doi: 10.1093/hmg/ddaa138. Hum Mol Genet. 2020. PMID: 32620959 Free PMC article.
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD.
Perrone RD, Hariri A, Minini P, Ahn C, Chapman AB, Horie S, Knebelmann B, Mrug M, Ong ACM, Pei YPC, Torres VE, Modur V, Gansevoort RT. Perrone RD, et al. Among authors: modur v. Kidney Med. 2022 Aug 27;4(10):100538. doi: 10.1016/j.xkme.2022.100538. eCollection 2022 Oct. Kidney Med. 2022. PMID: 36204243 Free PMC article.
Glycosphingolipid metabolism and polycystic kidney disease.
Natoli TA, Modur V, Ibraghimov-Beskrovnaya O. Natoli TA, et al. Among authors: modur v. Cell Signal. 2020 May;69:109526. doi: 10.1016/j.cellsig.2020.109526. Epub 2020 Jan 10. Cell Signal. 2020. PMID: 31911181 Free article. Review.
A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer.
Terzo E, Apte SA, Padhye S, Rashed S, Austin W, Caponegro M, Reddy A, Shi S, Wang C, Clark RB, Sidransky D, Modur V, Badarinarayana V. Terzo E, et al. Among authors: modur v. Cancer Res Commun. 2023 Jun 5;3(6):969-979. doi: 10.1158/2767-9764.CRC-22-0469. eCollection 2023 Jun. Cancer Res Commun. 2023. PMID: 37377612 Free PMC article.
41 results